Protagenic Therapeutics Terminates CFO Amidst Going Concern Warning
PTIX has more than doubled off its 52-week low of $0.25.
Summary
Protagenic Therapeutics announced the termination of its Chief Financial Officer, Alexander Arrow, effective April 30, 2026, following recent disclosures of a 'going concern' warning and material weaknesses.
Key Events · Executive and Board Changes · PTIX
-
CFO Termination Announced
Alexander Arrow, MD, the Chief Financial Officer, was notified on March 31, 2026, that his employment will be terminated effective April 30, 2026.
-
Context of Financial Distress
This termination occurs shortly after the company disclosed a 'going concern' warning and material weaknesses in internal controls in its last 10-Q filing on March 9, 2026.
Analysis · PTIX · Life Sciences
The termination of the Chief Financial Officer at Protagenic Therapeutics is a significant negative development, especially given the company's recent disclosure of a 'going concern' warning and material weaknesses in internal controls. The CFO is typically responsible for financial oversight and reporting, making their departure during a period of financial instability particularly concerning. Investors should monitor for further updates regarding financial leadership and the company's ability to address its 'going concern' issues.
At the time of this filing, PTIX was trading at $0.53 on OTC in the Life Sciences sector, with a market capitalization of approximately $959.4K. The 52-week trading range was $0.25 to $121.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.